The Federal Institute for Medicines and Medical Products (BfArM), which is responsible for drug legalization in Germany, announced on Saturday, April 11, that the drug against COVID-19 could be approved by the end of the year, APA reports citing DW.
According to him, while there is no vaccine against coronavirus and drugs for the treatment of lung disease COVID-19, experts are figuring out whether already approved drugs can help in case of illness. And so far, the effectiveness of not a single drug has been proven. According to Broich, since the beginning of the epidemic, his department has received a large number of applications and has approved eight clinical trials of existing drugs in patients with COVID-19.
Within a few weeks, the drug regulatory authority in Germany expects to receive the first reliable research results. “If the data are convincing, I’m sure that we will be able to give permission before the end of this year,” Karl Broich concluded.
The head of BfArM said in particular that several clinical trials of the active substance Remdesivir, which had previously been recommended by WHO, are being conducted. An emergency treatment program for patients with severe COVID-19 pneumonia in hospital settings was approved on April 3, although the drug did not receive official permission.